Expression And Significance Of CD₅₆ In Acute Myeloid Leukemia

PurposeTo understand the expression of CD56 in AML and the clinical features of patients with CD56+AML. To analyze the effects of CD56 antigen on the patients’ curative effect and survival time, so as to provide evidence for patients’ treatment and prognosis.Method To ananlyse immunophenotype of initial-treated adult AML patients in our hospital,to understand CD56 antigen expression in AML patients,the CD56 antigen co expression with other differentiation antigen and the clinical features of patients with CD56+AML, to observe the effects of CD56 antigen on the AML patients’ complete remission rate, relapse rate, disease-free survival and overall survival.Result 1.In 75 AML patients, 23 cases were detected with CD56, the expression of CD56 in M5 was the highest(46.7%), followed by M1(42.9%) and M2(36.4%), in M4 was low(11.1%), and no expression in M3. 2.The expression of CD71 and CD11 b in CD56 positive group is higher than the negative group, indicating that the difference was statistically significant(P < 0.05), but has nothing to do with age, sex, high white blood cell, and the expression of HLA-DR, CD33, CD38, CD117 and CD123. 3.The incidence of CD56 positive group was higher than that in the negative group, and the difference was statistically significant(P < 0.05). 4.The CR rate of CD56 positive group was 76.5%, slightly higher than that of negative group CR rate(65.6%), and the difference was statistically no significant(P > 0.05). 5.CD56 positive group and negative group were more likely to relapse, the recurrence rate of the positive group higher than the negative group, the difference was statistically significant(P<0.05). 6.The median DEF of CD56 positive group was 7 months, the median OS was 10 months. The median DEF of CD56 negative group was 14 months, the median OS was 15 months. The DEF and OS in CD56 negative group were longer than those of positive group, and the difference is statistically significant(P<0.05).Conclusion 1. The expression of CD56 antigen in AML patients was 30.7%, higher expression in M5, M1 and M2, M4 in the low expression of M3 have no expression. 2. The expression of CD11 b and CD71 in the CD56 positive group was higher than that in the negative group 3. CD56 antigen expression did not affect the induction of complete remission rate in patients with primary AML. 4. The expression of CD56 positive AML patients are more prone to extramedullary infiltration, The patients with CD56 positive are easy to relapse, and the disease free survival time and Overall survival time were shortened.